ReviewEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2022
New Biology of Pheochromocytoma and Paraganglioma.
Review in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Targeting Left Ventricular Mechanics In Patients With Pheochromocytoma/Paraganglioma: An Updated Meta-analysis.American journal of hypertension · 2023Pooled it
- PPGLomics: an interactive platform for pheochromocytoma and paraganglioma transcriptomics.Endocrine-related cancer · 2026Article
- Pre- and post-operative metabolic profile of patients with pheochromocytoma: A retrospective multicenter study.Endocrine · 2026Article
- Effects of catecholamines on bone and mineral metabolism in patients with pheochromocytoma and paraganglioma.The Journal of clinical endocrinology and metabolism · 2026Review
- Prognostic factors for cardiovascular complications induced by catecholamines in pheochromocytomas and paragangliomas: a systematic review and meta-analysis.Hormones (Athens, Greece) · 2026Article
- Convergent IGF2 overexpression in pheochromocytoma/paraganglioma: insights from Beckwith-Wiedemann syndrome.Endocrine-related cancer · 2026Article
- PPGLomics: An Interactive Platform for Pheochromocytoma and Paraganglioma Transcriptomics.bioRxiv : the preprint server for biology · 2026Article
- Belzutifan for HIF2A-Related Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026Article
- Pheochromocytoma complicated with acute myocardial infarction and cerebral infarction: a case report.Frontiers in oncology · 2026Article
- New Insights into the Clinical Characterization of SDHAF2-related Familial Paraganglioma Syndrome.The Journal of clinical endocrinology and metabolism · 2025Article
- Approach to the Patient With Metastatic Pheochromocytoma and Paraganglioma.The Journal of clinical endocrinology and metabolism · 2025Article
- Article
- CT angiography of the carotid body: bridging the gap between normal and neoplastic lesions.The British journal of radiology · 2025Article
- Pheochromocytoma in a patient with heterotaxy syndrome: a case report.BMC endocrine disorders · 2025Article
- Progress in surgical approaches and outcomes of patients with pheochromocytoma and paraganglioma.Best practice & research. Clinical endocrinology & metabolism · 2025Review
- Treatment with radiotherapy in carotidal paraganglioma: experience of the General Hospital of Mexico.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Article
- Diagnostic performance of [European radiology · 2024Article
- Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient.The Journal of clinical endocrinology and metabolism · 2024Review
- The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.Endocrine reviews · 2024Review
- Case Series:Frontiers in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Pheochromocytomas and paragangliomas continue to be defined by significant morbidity and mortality despite their several recent advances in diagnosis, localization, and management. These adverse outcomes are largely related to mass effect as well as catecholamine-induced hypertension, tachyarrhythmias and consequent target organ damage, acute coronary syndromes, and strokes (ischemic and hemorrhagic stroke). Thus, a proper understanding of the physiology and pathophysiology of these tumors and recent advances are essential to affording optimal care. These major developments largely include a redefinition of metastatic behavior, a novel clinical categorization of these tumors into 3 genetic clusters, and an enhanced understanding of catecholamine metabolism and consequent specific biochemical phenotypes. Current advances in imaging of these tumors are shifting the paradigm from poorly specific anatomical modalities to more precise characterization of these tumors using the advent and development of functional imaging modalities. Furthermore, recent advances have revealed new molecular events in these tumors that are linked to their genetic landscape and, therefore, provide new therapeutic platforms. A few of these prospective therapies translated into new clinical trials, especially for patients with metastatic or inoperable tumors. Finally, outcomes are ever-improving as patients are cared for at centers with cumulative experience and well-established multidisciplinary tumor boards. In parallel, these centers have supported national and international collaborative efforts and worldwide clinical trials. These concerted efforts have led to improved guidelines collaboratively developed by healthcare professionals with a growing expertise in these tumors and consequently improving detection, prevention, and identification of genetic susceptibility genes in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.